Zimmer Biomet is a medical devices business based in the US. Zimmer Biomet shares (ZBH) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $109.27 – a decrease of 2.91% over the previous week. Zimmer Biomet employs 18,000 staff and has a trailing 12-month revenue of around $7.6 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $109.27 |
|---|---|
| 52-week range | $101.47 - $133.31 |
| 50-day moving average | $106.13 |
| 200-day moving average | $114.81 |
| Wall St. target price | $124.92 |
| PE ratio | 20.7729 |
| Dividend yield | $0.96 (0.87%) |
| Earnings per share (TTM) | $5.24 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $110.95 from 2024-11-19
| 1 week (2024-11-14) | 1.93% |
|---|---|
| 1 month (2024-10-21) | 5.47% |
| 3 months (2024-08-21) | -1.05% |
| 6 months (2024-05-21) | -6.76% |
| 1 year (2023-11-21) | -1.73% |
|---|---|
| 2 years (2022-11-21) | -1.57% |
| 3 years (2021-11-19) | 121.9683 |
| 5 years (2019-11-21) | 132.8733 |
Valuing Zimmer Biomet stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zimmer Biomet's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Zimmer Biomet's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, Zimmer Biomet shares trade at around 21x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Zimmer Biomet's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4269. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Zimmer Biomet's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Zimmer Biomet's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.6 billion.
The EBITDA is a measure of a Zimmer Biomet's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $7.6 billion |
|---|---|
| Operating margin TTM | 18% |
| Gross profit TTM | $4.9 billion |
| Return on assets TTM | 4.61% |
| Return on equity TTM | 8.71% |
| Profit margin | 14.27% |
| Book value | $62.00 |
| Market Capitalization | $21.7 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Zimmer Biomet.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 40.16
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Zimmer Biomet's overall score of 40.16 (as at 12/31/2018) is pretty weak – landing it in it in the 77th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Zimmer Biomet is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 9.29/100
Zimmer Biomet's environmental score of 9.29 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Zimmer Biomet is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 23.4/100
Zimmer Biomet's social score of 23.4 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Zimmer Biomet is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 16.46/100
Zimmer Biomet's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Zimmer Biomet is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Zimmer Biomet scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Zimmer Biomet has, for the most part, managed to keep its nose clean.
Zimmer Biomet Holdings Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 40.16 |
|---|---|
| Total ESG percentile | 77.24 |
| Environmental score | 9.29 |
| Environmental score percentile | 9 |
| Social score | 23.4 |
| Social score percentile | 9 |
| Governance score | 16.46 |
| Governance score percentile | 9 |
| Level of controversy | 2 |
Dividend payout ratio: 12.17% of net profits
Recently Zimmer Biomet has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Zimmer Biomet shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Zimmer Biomet's case, that would currently equate to about $0.96 per share.
While Zimmer Biomet's payout ratio might seem low, this can signify that Zimmer Biomet is investing more in its future growth.
Zimmer Biomet's most recent dividend payout was on 30 October 2024. The latest dividend was paid out to all shareholders who bought their shares by 29 September 2024 (the "ex-dividend date").
Zimmer Biomet's shares were split on a 103:100 basis on 28 February 2022 . So if you had owned 100 shares the day before before the split, the next day you'd have owned 103 shares. This wouldn't directly have changed the overall worth of your Zimmer Biomet shares – just the quantity. However, indirectly, the new 2.9% lower share price could have impacted the market appetite for Zimmer Biomet shares which in turn could have impacted Zimmer Biomet's share price.
Over the last 12 months, Zimmer Biomet's shares have ranged in value from as little as $101.47 up to $133.3068. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zimmer Biomet's is 1.021. This would suggest that Zimmer Biomet's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Zimmer Biomet Holdings, Inc. , together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S. E. T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.